Dr Reddy’s Canada Semaglutide Nod: Key Details 2026

What Health Canada’s update means for Dr Reddy’s

Dr. Reddy’s Laboratories has been in focus after reporting progress in Canada for a generic semaglutide injection, a product category tied to the fast-growing GLP-1 therapy market. In company commentary, the drugmaker said Health Canada granted a Notice of Compliance (NOC) ahead of the regulator’s review target date. The approval described by the company covers 2 mg/pen and 4 mg/pen presentations.

But investor attention sharpened because another exchange communication referenced market reports and clarified that the company had not yet received the final NOC at that point. In that filing, Dr Reddy’s said it had received Drug Identification Numbers (DINs) on April 22, 2026, while continuing engagement with the regulator for the final NOC.

Product profile: semaglutide pens and indicated use

Semaglutide is the active ingredient in Novo Nordisk’s Ozempic, a widely used diabetes therapy. The molecule is part of the GLP-1 receptor agonist class, which has seen strong global demand for diabetes and weight management.

In the Canada-related disclosures, the market authorisation referenced pen presentations of 2 mg/pen and 4 mg/pen, with concentration stated as 1.34 mg/mL. The product is positioned to improve glycaemic control in adults with type 2 diabetes.

Why Canada is strategic in semaglutide

Dr Reddy’s described Canada as the world’s second-largest market for semaglutide. Coverage also cited a Canada semaglutide market size of about $1,300 million as of 2026.

The company said it is preparing to launch in Canada and framed the market as a priority as it expands access to GLP-1 therapies. CEO Erez Israeli said the milestone underscores Dr Reddy’s expertise in complex product development and peptide science, and its ability to meet stringent regulatory standards.

Mixed messaging: “NOC received” vs “still awaiting NOC”

The story carried two clear threads in the provided material. First, the company statement indicated an NOC was granted ahead of the target date. Second, a later stock exchange clarification addressed a media report and said the company had not yet received Health Canada approval (the NOC) for its semaglutide injection.

In the same clarification, Dr Reddy’s confirmed it received DINs on April 22, 2026, and said it would bring the product to the Canadian market upon approval. The DIN update was presented as a milestone within Canada’s regulatory pathway, while the company continued to work with Health Canada on remaining requirements.

Manufacturing and supply chain: in-house API and OneSource as CDMO

Dr Reddy’s said the active pharmaceutical ingredient (API) for the product is manufactured entirely in-house. The company linked this to its capabilities in peptide-based therapies and complex generics.

For formulation, commercial manufacturing support is to be provided by partner OneSource Specialty Pharma Limited, described as the contract development and manufacturing organisation (CDMO) for the programme. OneSource said it would support scale-up and commercial manufacturing from its US FDA-approved facility in Bengaluru. The stated aim of the partnership is reliable and scalable commercial supply.

What happened earlier: NON in 2025 and subsequent response

Dr Reddy’s previously disclosed that Health Canada issued a Notice of Non-Compliance (NON) in October 2025, seeking additional information on aspects of its Abbreviated New Drug Submission for semaglutide injection. Management said it submitted its response by mid-November 2025 within the stipulated timeline and has been awaiting the regulator’s response.

During a Q3 FY26 earnings call, CEO Erez Israeli said the company had submitted its response to the Pharmaceutical Drugs Directorate and was planning for a launch window between February and May, subject to approval. Management also said no plant inspections were expected or needed, while noting that additional regulatory queries can arise in normal processes.

Market reaction and brokerage view in India

As per latest NSE data included in the provided material, Dr Reddy’s shares were trading at ₹1,316, down ₹15 or 1.13%. Citi maintained a ‘Sell’ rating on Dr Reddy’s with a target price of ₹1,070 per share, and said a recent 9% rally on unconfirmed Canada approval news likely overstated the upside.

The combination of a high-profile product category and regulatory uncertainty contributed to tighter investor tracking of each milestone, including DINs, NON resolution, and the final NOC.

India angle: Obeda launch and GLP-1 market growth

Separately, Dr Reddy’s announced the launch of injectable semaglutide in India under the brand name Obeda for type 2 diabetes. The company said it was the first Indian company to receive DCGI approval for generic semaglutide.

In the Indian market, the reported cost to the patient for Obeda was ₹4,200 per month for 2 mg and 4 mg versions, described as a 62% drop from the highest dosage form of the innovator drug Ozempic. The India injectable GLP-1 agonist segment was reported at ₹1,446 crore in February 2026, with sales rising 177% on a moving annual turnover basis from ₹571 crore in February 2025 to ₹1,446 crore in February 2026.

Key facts at a glance

Market impact: why this matters for investors and the sector

Semaglutide is among the most watched molecules in diabetes care because demand extends into weight management. For Indian drugmakers, a Canada launch opportunity matters because it is a regulated market with higher-value complex generics.

The disclosures also reflect how peptide therapies and injectables are becoming an area of expansion for Indian pharmaceutical companies seeking regulated-market opportunities. Dr Reddy’s emphasis on in-house API and a CDMO partnership for commercial manufacturing highlights the operational requirements for scaling peptide-based injectables.

Analysis: the core issue is timing and regulatory clarity

From the information provided, the central investor question is the precise regulatory status in Canada: whether the NOC has been granted or is still pending, with DINs already issued. Each step influences launch preparedness and first-mover positioning, especially where market commentary described Canada as the second-largest semaglutide market.

At the same time, Dr Reddy’s broader GLP-1 strategy is visible in its India launch and in management commentary about introducing generic semaglutide in multiple countries under a “One Product, One Quality” approach. The company has also flagged that competition is expected eventually in Canada.

Conclusion

Dr Reddy’s updates on generic semaglutide in Canada put attention on its peptide capabilities, manufacturing partnerships, and the sequencing of regulatory milestones such as DINs and the final NOC. The company has said launch preparations are underway and that it remains engaged with Health Canada to bring the product to market upon approval. The next clear trigger for investors, based on the disclosures, is confirmation of the final NOC and the company’s Canada launch timing.